Biognosis buys Abion to serve as research & development centre:
This article was originally published in Clinica
Executive Summary
Biognosis has bought the assets of Abion, of Julich, Germany, and formed a new German subsidiary, Biognosis. The UK company, which is developing serology tests for infectious diseases, says Abion's technology supports its development of high speed, quantitative immunoassays. The German subsidiary will serve as Biognosis' R&D centre. High Wycombe-based Biognosis, which is privately-funded, plans to spend DM10 million ($5.6 million) on development projects over the next four years. The first are expected in mid-1999.